溶细胞性诱导治疗改善非裔美国肾移植受者临床结局
多变量回归显示溶细胞性诱导使急性排斥风险降低32%、移植物丢失风险降低9%、死亡风险降低12%,在致敏、公共保险、移植物功能延迟或撤除激素亚组中获益更显著。
要点
- 非裔美国肾移植受者中,溶细胞性诱导较IL-2RA降低急性排斥风险32%。
- 溶细胞性诱导还降低移植物丢失风险9%和死亡风险12%。
- 致敏、公共保险、移植物功能延迟或撤除激素者获益更明显。
核心结论
- 在成年非裔美国单纯肾移植受者中,与IL-2RA诱导相比,溶细胞性诱导降低急性排斥、移植物丢失和死亡风险。
研究设计与样本
- 全国队列研究,使用2000年1月1日至2009年12月31日美国移植登记库数据,纳入随访至少5年的成年非裔美国单纯肾移植受者。
- 采用多变量logistic回归和Cox回归评估急性排斥、移植物丢失和死亡,并设交互项评估效应修饰。
主要发现
- 显著效应修饰因素包括公共保险、群体反应性抗体、移植物功能延迟和撤除激素,这些亚组中溶细胞性诱导显著改善临床结局。
临床怎么用
- 对于非裔美国成人肾移植受者,可优先考虑溶细胞性诱导而非IL-2RA以降低排斥、移植物丢失和死亡风险。
- 对致敏、公共保险、发生移植物功能延迟或计划撤除激素的非裔美国受者,溶细胞性诱导的获益更显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Determine the impact of cytolytic versus IL-2 receptor antibody (IL-2RA) induction on acute rejection, graft loss and death in African-American (AA) kidney transplant (KTX) recipients. BACKGROUND: AAs are underrepresented in clinical trials in transplantation; thus, there is controversy regarding the optimal choice of perioperative antibody induction in KTX to improve outcomes. METHODS: National cohort study using US transplant registry data from January 1, 2000 to December 31, 2009 in adult solitary AA KTX recipients, with at least 5 years of follow-up. Multivariable logistic and Cox regression were utilized to assess the outcomes of acute rejection, graft loss, and mortality, with interaction terms to assess effect modification. RESULTS: Twenty-five thousand eighty-four adult AAs receiving solitary KTX were included, 16,927 (67.5%) received cytolytic induction and 8157 (32.5%) received IL-2RA induction. After adjustment for recipient sociodemographics, donor, and transplant characteristics, the use of cytolytic induction therapy reduced the risk of acute rejection by 32% (OR 0.68, 0.62-0.75), graft loss by 9% (HR 0.91, 0.86-0.97), and death by 12% (HR 0.88, 0.83-0.94). There were a number of significant effect modifiers, including public insurance, panel reactive antibody, delayed graft function, and steroid withdrawal; in these groups, cytolytic induction substantially improved clinical outcomes. CONCLUSIONS: These data demonstrate that cytolytic induction therapy, as compared with IL-2RA, reduces the risk of rejection, graft loss, and death in adult AA KTX recipients, particularly in those who are sensitized, receive public insurance, develop delayed graft function, or undergo steroid withdrawal.
引用
- Taber DJ, McGillicuddy JW, Bratton CF, et al. Cytolytic Induction Therapy Improves Clinical Outcomes in African-American Kidney Transplant Recipients. Ann Surg. 2017. PMID: 28654544. doi:10.1097/SLA.0000000000002366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。